Antithrombin Market 2021 | Global Size, Share, Comprehensive Research Study, Regional Trends, Business Growth, Competitive Landscape, Emerging Opportunities and Forecast to 2027
SEATTLE, April 09, 2021, (PHARMIWEB) — Antithrombin is a protein present in blood that inactivates thrombin to restrict blood clotting. The protein in produced by liver and contains 432 amino acids. There are two types of antithrombin deficiency and inherited antithrombin deficiency. Antithrombin deficiency caused due to other diseases such as nephrotic syndrome, liver failure, severe trauma, and metastatic tumors is called acquired antithrombin deficiency, whereas inherited antithrombin deficiency is caused due to a genetic mutation or abnormality. According to National Center for Biotechnology Information (NCBI), inherited antithrombin deficiency is a rare deficiency that occurs in only 0.2% of the global population.
A sample of this report is available upon request @ https://www.coherentmarketinsights.com/insight/request-sample/2018
ATryn is a widely used drug for the treatment of antithrombin deficiency. The drug, developed by rEVO Biologics, received the U.S. Food and Drug Administration (FDA) approval in 2009. Antithrombin shows synergistic activity with heparin that enhances the antithrombin binding with Thrombin (factor II a) and Factor Xa. Antithrombin III blood test is used to measure the extent of antithrombin deficiency.
High prevalence of coagulation disorders is expected to augment the market growth
Increasing prevalence of coagulation disorders and high number of open heart surgeries and extracorporeal circulation during hemodialysis is expected to boost growth of the global antithrombin market. For instance, according to the Centers for Disease Control and Prevention (CDC), 2015, around 900,000 people are affected from venous thromboembolism, annually in the U.S. Moreover, 5 to 8% of the U.S. population has increased risk of suffering from thrombosis due to one of the several genetic risk factors known as inherited thrombophilia.
Key players in the market are focused on developing advanced administering technologies, which is also expected to boost growth of the antithrombin market. For instance, Fitusiran (ALN-AT3), developed by Alnylam Pharmaceuticals, Inc., is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT). This therapeutic can be used for the treatment of hemophilia and rare bleeding disorders (RBDs). It is in late stage (Phase 2-phase 3) clinical trial. Moreover, GTC Biotherapeutics, Inc.’s product called as ATryn Antithrombin (Recombinant), derived from human blood donors, is used for hereditary antithrombin deficiency. The therapy recently received market approval in the U.S.
Moreover, increasing use of antithrombin+ heparin in combination is also expected to propel growth of the market. Heparin resistance in cardiac surgery is expected to boost adoption of antithrombin products in anticoagulation therapy.
Major regulatory bodies have imposed regulations on drug testing on animals, which has increased challenges in drug development. This in turn is expected to hinder the market growth.
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2018
Antithrombin Market – Regional Analysis
Increasing adoption of robust technologies and antithrombin therapies and high awareness of antithrombin among the populace is expected to boost growth of the market in North America and Europe. Moreover, increasing regulatory approvals of drugs in these regions is also expected to aid in growth of the markets.
The market in Asia Pacific is majorly driven by significant improvements in the healthcare infrastructure in emerging economies of China and India. Key players in the market are focused on product approval and launch to expand their product portfolio. For instance, in 2016, China Biologic Products, Inc.’s subsidiary, Shandong Taibang Biological Products Co. Ltd., obtained approval from the China Food and Drug Administration (CFDA) to begin human clinical trials using its Human Antithrombin III (ATIII) product for the treatment of hereditary and acquired ATIII deficiency, which are more prone during surgical or obstetrical procedures, and treatment of thromboembolism.
Antithrombin Market – Competitive Landscape
Key players operating in the global antithrombin market include, GTC Biotherapeutics, Inc.’s, Green Cross Corp., Grifols, Shire Plc., rEVO Biologics Inc., CSL Limited, Kedrion S.p.A, Lee Bisolutions, Scripps Laboratories Inc., and BDI Pharma.
Antithrombin Market – Taxonomy
On the basis of application, the global antithrombin market is segmented into:
On the basis of source, the global antithrombin market is segmented into:
- Goat Milk
On the basis of dosage form, the global antithrombin market is segmented into:
On the basis of region, the global antithrombin market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire